Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Operating Leases (2019 - 2025)

China Pharma Holdings filings provide 7 years of Operating Leases readings, the most recent being $111548.0 for Q4 2025.

  • On a quarterly basis, Operating Leases rose 183.67% to $111548.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $111548.0, a 183.67% increase, with the full-year FY2025 number at $111548.0, up 183.67% from a year prior.
  • Operating Leases hit $111548.0 in Q4 2025 for China Pharma Holdings, down from $198583.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $198583.0 in Q3 2025 to a low of $20008.0 in Q1 2024.
  • Median Operating Leases over the past 5 years was $73863.0 (2021), compared with a mean of $79482.4.
  • Biggest five-year swings in Operating Leases: skyrocketed 307.55% in 2022 and later tumbled 81.08% in 2023.
  • China Pharma Holdings' Operating Leases stood at $85282.0 in 2021, then crashed by 52.57% to $40445.0 in 2022, then dropped by 1.32% to $39910.0 in 2023, then dropped by 1.47% to $39323.0 in 2024, then soared by 183.67% to $111548.0 in 2025.
  • The last three reported values for Operating Leases were $111548.0 (Q4 2025), $198583.0 (Q3 2025), and $39323.0 (Q4 2024) per Business Quant data.